Aimmune Therapeutics climbs, Planet Fitness falls in market debuts

Shares of Aimmune Therapeutics Inc. jumped in their market debut on Thursday, while Planet Fitness' stock declined.

Aimmune, a biopharmaceutical company developing treatments for peanut allergy and other food allergies, raised $160 million from its initial public offering of 10 million shares. The offering priced at $16 per share.

The company is giving the underwriters a 30-day option to buy up to an additional 1.5 million shares.

The stock leapt $5.48, or 34.3 percent, to $21.48 in midday trading on the Nasdaq. It is trading under the "AIMT" ticker symbol.

Elsewhere, Planet Fitness raised $216 million from its IPO of 13.5 million shares. The offering priced at $16 per share.

The fitness center operator and certain selling stockholders are giving the underwriters a 30-day option to buy up to an additional 2 million shares.

Shares of Planet Fitness Inc. shed 20 cents to $15.80. It is listed on the New York Stock Exchange under the "PLNT" ticker symbol.